Laura Shawver - Apr 7, 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Director
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Apr 7, 2025
Transactions value $
-$372,565
Form type
4
Date filed
4/8/2025, 04:45 PM
Previous filing
Mar 7, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $109K +22.5K +10.7% $4.85 233K Apr 7, 2025 Direct
transaction SPRY Common Stock Options Exercise $133K +27.5K +11.81% $4.85 260K Apr 7, 2025 Direct
transaction SPRY Common Stock Sale -$615K -50K -19.21% $12.30 210K Apr 7, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -22.5K -30.39% $0.00 51.6K Apr 7, 2025 Common Stock 22.5K $4.85 Direct F3
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -27.5K -53.33% $0.00 24.1K Apr 7, 2025 Common Stock 27.5K $4.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
F2 The weighted average sale price for the transaction reported was $12.301 and the range of prices were between $12.0063 and $12.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 Immediately exercisable.